Wills Eye Glaucoma Service
Philadelphia, Pennsylvania, 19107, United States
NCT Number: NCT00405431
The purpose of this study is to determine whether reducing inflammation of the surface of the eye with topical Restasis after glaucoma surgery will improve surgical outcomes and increase patient comfort.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Philadelphia, Pennsylvania, 19107, United States
Continued use of glaucoma drops can alter the outer surface of the eye and result in swelling and irritation, changing the structure of the eye. This structural change has been found to be a significant risk factor for the failure of glaucoma surgery. A comparison of how well patients do after glaucoma surgery depending on whether they use Restasis (the only prescription medication approved by the FDA for treating dry eye) or artificial tears (which can be purchased without a prescription) for 6 months following their surgery.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
1 drop in study eye twice a day X 6 months
1 drop in study eye twice a day X 6 months
Other names: Endura
Time frame: 6 months
Time frame: 6 months
Wills Eye
Other
Influence of Post-Operative Cyclosporine 0.05% (Restasis) on the Success of Glaucoma Filtering Surgery
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07592988
Eye Diseases, Glaucoma
Almaty, Kazakhstan
View Trial DetailsNCT07592923
Eye Diseases, Glaucoma
Almaty, Kazakhstan
View Trial DetailsNCT03076697
Age Related Macular Degeneration, Cardiovascular Diseases
View Trial DetailsNCT07763288
Blind Eye, Blindness
Nonthaburi, Thailand
View Trial Details